Catabasis Pharmaceuticals, Inc.
161 First Street
Suite 1A
Cambridge
Massachusetts
02142
United States
Tel: 617-349-1971
Fax: 617-273-2637
Website: http://www.catabasispharma.com/
Email: info@catabasispharma.com
211 articles about Catabasis Pharmaceuticals, Inc.
-
Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus
9/8/2021
Catabasis Pharmaceuticals, Inc. today announced its name, Astria Therapeutics, Inc.
-
Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
8/9/2021
Catabasis Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
-
Catabasis Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference
8/4/2021
Catabasis Pharmaceuticals, Inc. today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the upcoming virtual Wedbush PacGrow Healthcare Conference on Tuesday, August 10 th , 2021 at 8:35am ET.
-
Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference
7/7/2021
Catabasis Pharmaceuticals, Inc. today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the upcoming virtual Ladenburg Thalmann Healthcare Conference.
-
Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences
5/14/2021
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the following upcoming virtual investor conferences
-
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
3/11/2021
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.
-
Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences
3/2/2021
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and provide information about our lead program QLS-215, in preclinical development for the treatment of hereditary angioedema, at the following virtual investor conferences this month:
-
Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.
1/29/2021
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that it has acquired Quellis Biosciences Inc. (“Quellis”), a privately-held emerging biopharmaceutical company focused on discovering best-in-class new molecules to treat serious rare diseases.
-
Catabasis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
11/12/2020
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update. As previously reported, the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD) did not meet the primary endpoint, change fr
-
Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy
10/26/2020
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD) did not meet the primary endpoint, which was a change from baseline in the North Star Ambulatory Assessment (NSAA) over one year of edasalonexent compared to p
-
Catabasis Pharmaceuticals Presents Information on Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy, at the Virtual 25th International Congress of the World Muscle Society
9/28/2020
Catabasis Pharmaceuticals Presents Information on Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy, at the Virtual 25 th International Congress of the World Muscle Society -- New Preclinical Research Indicates that Edasalonexent Could Have Positive Effects on Cardiac Function and Preserve Bone Health --
-
Catabasis Pharmaceuticals Names Noah Clauser Chief Financial Officer
9/21/2020
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it has promoted Noah Clauser to Chief Financial Officer
-
Catabasis Pharmaceuticals to Present at Upcoming Virtual Investor Conferences
9/8/2020
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and provide information about edasalonexent, in Phase 3 development for the treatment of Duchenne muscular dystrophy, at the following virtual investor conferences this month: HC Wainwright 22 nd Annual Global Investment Conf
-
Catabasis Pharmaceuticals to Host Virtual KOL Event on Edasalonexent and Duchenne Muscular Dystrophy
9/2/2020
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will be holding a virtual key opinion leader (KOL) event to discuss edasalonexent, currently in Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD), on Friday, September 11, . 2020 at 9:00am ET. The event will feature a discussion with Craig McDonald, M.D., Director, Neuromuscular Disease Clinics at UC
-
Catabasis Pharmaceuticals to Present at Virtual 2020 Wedbush PacGrow Healthcare Conference
8/5/2020
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at the virtual 2020 Wedbush PacGrow Healthcare Conference on Wednesday, August 12, 2020 at 8:00am ET. A webcast of the presentation will be available on the investors section of the Company’s website, www.catabasis.com , and will be
-
Catabasis Pharmaceuticals and Bill & Melinda Gates Medical Research Institute to Study CAT-5571 in Drug-Sensitive and Drug-Resistant Tuberculosis
8/4/2020
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today it entered into an agreement with the Bill & Melinda Gates Medical Research Institute (Gates MRI), a non-profit biotechnology organization, to assess CAT-5571 as a potential oral therapy to promote autophagy and clear persistent lung infections in patients with both drug-sensitive and drug-resistant tuberculosis (TB). C
-
Catabasis Pharmaceuticals to Report Second Quarter 2020 Financial Results on Monday, August 10th
7/27/2020
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report second quarter 2020 financial results after the Nasdaq Global Market close on Monday, August 10, 2020. About Catabasis At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients
-
Catabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy Virtual Annual Conference
7/15/2020
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it will present information on the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD) at the Parent Project Muscular Dystrophy (PPMD) Virtual Annual Conference, which begins Wednesday, July 22, 2020. Joanne Donovan, M.D., Ph.D, Chief Medical Officer of Catabasis,
-
Catabasis Joins Russell 3000® Index
6/29/2020
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it has joined the broad-market Russell 3000® Index at the conclusion of the 2020 Russell Indexes annual reconstitution, effective after the US market opened today.
-
Catabasis Pharmaceuticals Names Ben Harshbarger Senior Vice President, General Counsel
6/12/2020
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it has named Ben Harshbarger as Senior Vice President, General Counsel. Mr. Harshbarger brings to Catabasis more than 20 years of experience at commercial-stage pharmaceutical and biotechnology companies. “Ben brings to Catabasis extensive senior legal and compliance experience in the pharmaceutical industry, inc